The US Association for Accessible Medicines has praised the US Department of Health and Human Services and the Center for Medicare & Medicaid Services for their recommendation that health plans be required to place generic and branded drugs on their own specialized tiers as part of the Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2024.
US Government Proposals Would Obligate Health Plans To Place Generics On Correct Tiers
HHS And CMS Recommendation Has Been Welcomed By The AAM
The HHS and CMS have proposed that health plans in the US be required to place generic and brand drugs on the correct tiers for their drug category.
More from Generics
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.